Key result
FEIBA improves joint and muscle bleeding resolution by ~12 percentage points over nonactivated control.
RCT (n=15)
Double-blind
Answers are grounded in this paper and cite their sources.
We designed a double-blind trial to study the effect of an "activated" prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in hemophiliacs with antibodies to factor VIII. Fifteen patients received either FEIBA or the control preparation (a nonactivated prothrombin-complex concentrate) for a total of 150 bleeding episodes (four mucocutaneous bleeding, 117 joint bleeding, and 29 muscle bleeding). In 64 per cent of the episodes, FEIBA was judged by the physician to be effective; the control preparation was perceived as effective in 52 per cent of the episodes in which it was used. Pairwise comparison of FEIBA and the control preparation for bleeding in the same joint or muscle showed a significantly better result with FEIBA (P = 0.0085). Joint mobility after the use of FEIBA was significantly improved (P = 0.006). There was a high incidence of hepatitis (three of the 15 patients) and of transient disturbances of liver function (nine of 15) during the 15-month observation period.
No takes yet. Share an insight, caveat, or question.
Sjamsoedin et al. (1981) conducted an RCT in Hemophilia A with antibodies to factor VIII (n=15). Activated prothrombin-complex concentrate (FEIBA) vs. Nonactivated prothrombin-complex concentrate was evaluated on Physician-judged effectiveness for bleeding episodes (p=0.0085). Activated prothrombin-complex concentrate (FEIBA) was more effective than a nonactivated control at treating joint and muscle bleeding episodes.
Synapse has enriched 10 related papers. Consider them for comparative context: